Alistair Lax

Prof. Alistair Lax

orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2002 in Trends in Microbiology
Verified
Journal Article
Closed access
ALAlistair Lax
Alistair Lax
WTWarren Thomas
Warren Thomas

1 April 2005 in Nature Reviews Microbiology
Verified
Journal Article
Closed access
ALAlistair Lax
Alistair Lax

31 January 2019 in Gut Microbes
Verified
Journal Article
Closed access
LBLucy E. Blandford
Lucy E. Blandford
EJEmma L. Johnston
Emma L. Johnston
JSJeremy D. Sanderson
Jeremy D. Sanderson
WWWilliam G. Wade
William G. Wade
ALAlistair Lax
Alistair Lax
Bacteroides fragilis is a member of the normal microbiota of the lower gastrointestinal tract, but some strains produce the putative tumourigenic B. fragilis toxin (BFT). In addition, B. fragilis can produce multiple capsular polysaccharides that comprise a microcapsule layer, including an immunomodulatory, zwitterionic, polysaccharide A (PSA) capable of stimulating anti-inflammatory interleukin-10 (IL-10) production. It is known that the PSA promoter can undergo inversion, thereby regulating the expression of PSA. A PCR digestion technique was used to investigate B. fragilis capsular PSA promoter orientation using human samples for the first time. It was found that approximately half of the B. fragilis population in a healthy patient population had PSA orientated in the ‘ON’ position. However, individuals with inflammatory bowel disease (IBD) had a significantly lower percentage of the B. fragilis population with PSA orientated ‘ON’ in comparison with the other patient cohorts studied. Similarly, the putative tumourigenic bft-positive B. fragilis populations were significantly associated with a lower proportion of the PSA promoter orientated ‘ON’. These results suggest that the proportion of the B. fragilis population with the PSA promoter ‘ON’ may be an indicator of gastrointestinal health.

1 January 2001 in International Journal of Medical Microbiology
Verified
Journal Article
Closed access
ALAlistair Lax
Alistair Lax
AGAgamemnon E. Grigoriadis
Agamemnon E. Grigoriadis

1 November 2001 in Infection and Immunity
Verified
Journal Article
Closed access
PDF file
WTWarren Thomas
Warren Thomas
ZAZoe K. Ascott
Zoe K. Ascott
DHDympna Harmey
Dympna Harmey
LSLee W. Slice
Lee W. Slice
EREnrique Rozengurt
Enrique Rozengurt
ALAlistair Lax
Alistair Lax
Cytotoxic necrotizing factor 1 (CNF) is a toxin produced by some isolates of Escherichia coli that cause extraintestinal infections. CNF can initiate signaling pathways that are mediated by the Rho family of small GTPases through a covalent modification that results in constitutive activation. In addition to regulating the assembly of actin stress fibers and focal adhesion complexes, RhoA can also regulate gene expression at the level of transcription. Here we demonstrate for the first time, by using a luciferase-based reporter system, that the transcription of cyclooxygenase-2 (COX-2) is strongly upregulated in NIH 3T3 fibroblasts treated with CNF and that this effect is dependent upon the activation of RhoA by the toxin. Subsequent protein tyrosine phosphorylation events modulate the induction, but the transcription signal is not mediated by Rho-associated kinase (p160/ROCK) and so must rely upon another effector that is activated by RhoA. CNF therefore induces COX-2 expression via a RhoA-dependent signaling pathway that diverges from the pathway that regulates cytoskeletal rearrangements in response to RhoA activation.

1 January 2004 in International Journal of Medical Microbiology
Verified
Journal Article
Closed access
ALAlistair Lax
Alistair Lax
GPGillian D. Pullinger
Gillian D. Pullinger
MBMichael Baldwin
Michael Baldwin
DHDympna Harmey
Dympna Harmey
AGAgamemnon E. Grigoriadis
Agamemnon E. Grigoriadis
JLJeremy H. Lakey
Jeremy H. Lakey